

Influenza

**A study to look at the safety and effectiveness of baloxavir marboxil in treating children with influenza aged between 1 and <12 years (miniSTONE-2)**

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

**Trial Status**  
Completed

**Trial Runs In**  
7 Countries

**Trial Identifier**  
NCT03629184 2018-002169-21  
CP40563

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to <12 years of age) with influenza-like symptoms.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03629184 2018-002169-21 CP40563**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=1 Year & <= 11 Years

**Healthy Volunteers**  
No

---